Tag Archives: budesonide oral suspension

June, 2016

30 June
Merrimack’s Pancreatic Cancer Regimen Maintains QOL While Improving Overall Survival in Clinical Trial

CAMBRIDGE, Mass., June 30, 2016 /PRNewswire/ — Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced a newly presented analysis of the Phase 3 NAPOLI-1 data shows patients treated with ONIVYDE® (irinotecan liposome injection), also known as “nal-IRI,” in combination with fluorouracil (5-FU) and leucovorin, maintain similar baseline quality of life at …
Share
13 June
FDA Grants Breakthrough Therapy Designation for Two of Shire’s Rare GI Drugs

Lexington, Mass. – June 13, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for two investigational products for rare diseases: SHP621 (budesonide oral suspension, or BOS) for eosinophilic esophagitis (EoE), and SHP625 (maralixibat) for progressive …
Share